Latest & greatest articles for bupropion

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on bupropion or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on bupropion and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for bupropion

21. Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Effects of Naltrexone Sustained- Release/Bupropion Sustained Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes 24144653 2013 11 22 2014 12 11 2016 12 15 1935-5548 36 12 2013 Dec Diabetes care Diabetes Care Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. 4022-9 10.2337/dc13-0234 To assess (...) the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53

EvidenceUpdates2013 Full Text: Link to full Text with Trip Pro

22. Prolonged release naltrexone and bupropion (Contrave) for the management of obesity

Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity Prolonged release naltrexone and bupropion (Contrave) for the management of obesity NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Prolonged release (...) naltrexone and bupropion (Contrave) for the management of obesity. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Naltrexones; Narcotic Antagonists; Obesity; Weight Loss Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning

Health Technology Assessment (HTA) Database.2013

23. Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments Executive Summary 1 Translation of the executive summary of the final report “Kosten-Nutzen-Bewertung von Venlafaxin, Duloxetin, Bupropion und Mirtazapin im Vergleich zu weiteren verordnungsfähigen medikamentösen Behandlungen” (Version 1.0; Status: 3 September 2013). Please note: This translation is provided as a service by IQWiG to English-language (...) readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. G09-01 Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments 1 Executive summary of final report G09-01 Version 1.0 Health economic evaluation of venlafaxine, duloxetine, bupropion, mirtazapine 3 Sep 2013 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details

Institute for Quality and Efficiency in Healthcare (IQWiG)2013

24. Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults.

Review: Varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. ACP Journal Club. Review: varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My (...) Bibliography Citation manager Format Create File 1 selected item: 22986399 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2012 Sep 18;157(6):JC3-7. doi: 10.7326/0003-4819-157-6-201209180-02007. ACP Journal Club. Review: varenicline is better than bupropion but not nicotine patch for smoking abstinence in adults. , . Comment on [Cochrane

Annals of Internal Medicine2012

25. Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome

Bupropion for Smoking Cessation in Patients With Acute Coronary Syndrome 21403011 2011 06 28 2011 09 09 2013 11 21 1538-3679 171 12 2011 Jun 27 Archives of internal medicine Arch. Intern. Med. Bupropion for smoking cessation in patients with acute coronary syndrome. 1055-60 10.1001/archinternmed.2011.72 Smokers hospitalized with acute coronary syndrome (ACS) are at high risk for subsequent ischemic events. Nevertheless, over two-thirds of patients continue to smoke after an acute (...) myocardial infarction. Bupropion hydrochloride has proven efficacy as a smoking cessation aid, but data regarding its safety and efficacy in ACS patients are limited. In a double-blind, randomized controlled trial, we compared the safety and efficacy of 8 weeks of treatment with bupropion slow-release (SR) or placebo for smokers hospitalized with ACS as an adjunct to nurse-led hospital- and telephone-based support. Primary efficacy outcome was smoking abstinence at 1 year. Primary safety outcome was clinical events

EvidenceUpdates2011

26. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.1 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.1; Status: 30.05.2011). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression 30.05.2011 Institute for Quality and Efficiency in Health Care (IQWiG) Version 1.1 - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal

Institute for Quality and Efficiency in Healthcare (IQWiG)2011

27. Forfivo XL (bupropion hydrochloride 450 mg extended-release) tablets

Forfivo XL (bupropion hydrochloride 450 mg extended-release) tablets Drug Approval Package: Forfivo XL (bupropion hydrochloride) NDA #022497 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - FORFIVO XL (bupropion hydrochloride 450 mg extended-release) tablets Company: IntelGenx Corp Application No.: 022497 Approval Date: 11/10/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

FDA - Drug Approval Package2011

28. Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia

Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Article Text Therapeutics Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia Free A Eden Evins

Evidence-Based Mental Health2010

29. Use of bupropion in patients with depression and the associated risk of seizures: safety

Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Use of bupropion in patients with depression and the associated risk of seizures: safety Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Use of bupropion in patients with depression and the associated risk of seizures: safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions The available evidence of an increased risk of seizures in patients treated with bupropion for depression was inconclusive. This evidence was, however, limited to uncontrolled studies rated as low quality by the authors of the AHRQ

Health Technology Assessment (HTA) Database.2010

30. Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder

Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder Developing Thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after (...) the failure of an SSRI for major depressive disorder Leelahanaj T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of switching from citalopram to bupropion monotherapy versus bupropion in addition

NHS Economic Evaluation Database.2010

31. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse

Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published (...) health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bupropion for adults with attention deficit hyperactivity disorder: a review of the clinical effectiveness and harms of misuse . Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2010 Authors' conclusions RCTs examining the efficacy of bupropion in adult ADHD frequently reported no

Health Technology Assessment (HTA) Database.2010

32. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of varenicline compared with bupropion or no aid for smoking cessation in Finland. The authors concluded that varenicline was more effective and resulted in cost savings

NHS Economic Evaluation Database.2010

33. Randomised controlled trial: Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined

Randomised controlled trial: Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined | Evidence-Based Nursing This site uses (...) Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined Article Text Therapeutics Randomised controlled trial Nicotine patch plus lozenge gives greatest increases in abstinence from smoking at 6 months compared with placebo; smaller effects seen with nicotine patch alone, bupropion or nicotine lozenges alone or combined Lynne Buchanan Correspondence

Evidence-Based Nursing (Requires free registration)2010

34. Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months

Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: varenicline, bupropion, and nicotine replacement therapies are effective for smoking cessation at 6 or 12 months Article Text Treatment Review: varenicline, bupropion, and nicotine replacement therapies

Evidence-Based Nursing (Requires free registration)2010

35. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 20673995 2010 08 23 2010 09 07 2016 06 22 1474-547X 376 9741 2010 Aug 21 Lancet (London, England) Lancet Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 595-605 10.1016/S0140-6736(10)60888-4 Despite increasing (...) public health concerns regarding obesity, few safe and effective drug treatments are available. Combination treatment with sustained-release naltrexone and bupropion was developed to produce complementary actions in CNS pathways regulating bodyweight. The Contrave Obesity Research I (COR-I) study assessed the effect of such treatment on bodyweight in overweight and obese participants. Men and women aged 18-65 years who had a body-mass index (BMI) of 30-45 kg/m(2) and uncomplicated obesity or BMI 27

Lancet2010

36. Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0

Bupropion, mirtazapine, and reboxetine in the treatment of depression; version 1.0 Executive Summary IQWiG Reports – Commission No. A05-20C Bupropion, mirtazapine, and reboxetine in the treatment of depression 1 1 Translation of the executive summary of the final report “Bupropion, Mirtazapin und Reboxetin bei der Behandlung der Depression” (Version 1.0; Status: 09.11.2009). Please note that this translation is provided as a service by IQWiG to English-language readers. However, solely (...) the German original text is absolutely authoritative and legally binding. Executive summary of final report A05-20C Bupropion, mirtazapine, and reboxetine in depression Version 1.0 09.11.2009 Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Bupropion, mirtazapine, and reboxetine in the treatment of depression Contracting agency: Federal Joint Committee Commission awarded on: 22.02.2005 Internal Commission No.: A05-20C Publisher’s address: Institute for Quality

Institute for Quality and Efficiency in Healthcare (IQWiG)2009

37. Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003

Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Varenicline as compared to bupropion in smoking-cessation therapy: cost-utility results for Sweden 2003 Bolin K, Mork A C, Willers S, Lindgren B Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of varenicline in comparison with bupropion in smoking-cessation programmes for smokers aged 18 years or older. The authors concluded that varenicline was a cost-effective alternative to bupropion in Sweden. The study was based on robust methodology, which enhances the validity

NHS Economic Evaluation Database.2008

38. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands Hoogendoorn M, Welsing P, Rutten-van Molken M P Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the long-term cost-effectiveness of varenicline to support smoking cessation in comparison with no treatment, bupropion, nortriptyline, or nicotine-replacement therapy (NRT). The authors concluded that varenicline was cost-effective compared

NHS Economic Evaluation Database.2008

39. Review: bupropion and nortriptyline each increase smoking cessation rates

Review: bupropion and nortriptyline each increase smoking cessation rates Review: bupropion and nortriptyline each increase smoking cessation rates | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: bupropion and nortriptyline each increase smoking cessation rates Article Text Therapeutics Review: bupropion and nortriptyline each increase smoking cessation rates Free Allan V Prochazka , MD, MSc Statistics from Altmetric.com No Altmetric data available for this article. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation

Evidence-Based Medicine (Requires free registration)2006

40. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden

The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden Bolin K, Lindgren B, Willers S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of bupropion tablets (Zyban, GlaxoSmithKline), two 150-mg tablets per day, with nicotine replacement therapy (patches or gum) as part of a smoking cessation programme. Type of intervention Public health intervention: smoking cessation programme. Economic study type Cost-utility analysis. Study population The study

NHS Economic Evaluation Database.2006